Polygel Dual: New Claims from BARRIER Study

Select Content Type
Resources
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
Barrier study_thmbnl
Detail Image
Barrier study_detail
Book Detail
Actions
Download in App
Countries of release
India
Nigeria
UAE
IS_Ebsco
false
Description

For the first time in Nigeria, the BARRIER study, a randomized controlled clinical trial evaluated and compared multiple liquid antacid brands in 220 patients.

Of the four brands assessed, one demonstrated consistent and statistically significant symptom improvement, with marked reductions in the severity and frequency of heartburn, regurgitation, and dyspepsia as early as Day 2. This brand also provided rapid onset of relief in under five minutes, with sustained comfort reported by 96% of patients and high overall satisfaction scores.

Click to learn more and discover which brand emerged as the most effective in antacid performance.

Published Date